SAN DIEGO, March 14, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today reported that the U.S. Food and Drug Administration has agreed with the recommendation of the independent Data Safety Monitoring Board (DSMB) to advance Difimicin (OPT-80/PAR101) into Phase 3 clinical studies.
